Hamburg Says Distrust Leaves FDA Vulnerable To Meddling
This article was originally published in The Tan Sheet
An atmosphere of distrust in government makes FDA vulnerable to congressional meddling, says Commissioner Margaret Hamburg.
You may also be interested in...
House Cuts WIC Funding In Appropriations Bill
The House passes a fiscal 2012 appropriations bill with significant cuts to a program that provides infant formula for low-income women.
At Tofersen Panel Review, US FDA Shined A Light On Internal Differences Of Opinion
Agency’s presentations on Biogen/Ionis’ ALS drug included differing viewpoints from the statistical and clinical pharmacology teams; the transparency and emphasis on a multidisciplinary review approach may reflect lessons learned from missteps at the Aduhelm panel review in 2020.
BrainStorm’s ALS Treatment NurOwn, Filed Over Protest, Will Get US FDA Panel Review
A November 2022 refuse-to-file letter cited clinical and statistical issues for the stem cell therapy, which failed its Phase III clinical efficacy endpoint. However, BrainStorm has consistently asserted that NurOwn demonstrated benefit in patients with less advanced disease at baseline, and it is encouraged by regulatory flexibility FDA recently has shown for the neurodegenerative disease.